Thrombocytopenia · CRRT
It is very uncertain whether unfractionated heparin changes thrombocytopenia compared with low molecular weight heparin (very low certainty).
1 finding from 1 review
Thrombocytopenia · CRRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · CRRT
Citrate showed no clear difference in thrombocytopenia compared with unfractionated heparin (low certainty).
1 finding from 1 review
Thrombocytopenia · glioblastoma in adults
Anti‐EGFR therapy showed no clear difference in thrombocytopenia compared with placebo or standard of care (low certainty).
1 finding from 1 review
Thrombocytopenia · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) may leads to higher thrombocytopenia compared with calcineurin inhibitors (CNI): secondary outcomes (low certainty).
1 finding from 1 review
Thrombocytopenia · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) may leads to higher thrombocytopenia compared with antimetabolites: secondary outcomes (low certainty).
1 finding from 1 review
Thrombocytopenia · primary immunosuppression in kidney transplant recipients
Low may leads to lower thrombocytopenia compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (low certainty).
1 finding from 1 review
Thrombocytopenia · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in thrombocytopenia compared with UFH prophylaxis (moderate certainty).
1 finding from 1 review
Thrombocytopenia · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in thrombocytopenia compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review
Thrombocytopenia
Heparin prophylaxis showed no clear difference in thrombocytopenia compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Intervention not reported
Heparin‐induced thrombocytopenia (HIT) · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days
The intervention may leads to lower heparin‐induced thrombocytopenia (HIT) (low certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · patients with metastatic bone pain
Radioisotopes showed no clear difference in thrombocytopenia III‐IV compared with placebo (low certainty).
1 finding from 1 review
Grade 1 ‐ 4 thrombocytopenia · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus mitomycin C changes grade 1 ‐ 4 thrombocytopenia compared with capecitabine plus mitomycin C (very low certainty).
1 finding from 1 review
Intervention not reported
Thrombocytopenia (grade 3/4) · women with newly diagnosed EOC (stage Ic to IV)
The intervention leads to higher thrombocytopenia (grade 3/4) (high certainty).
1 finding from 1 review
Thrombocytopenia · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · patients with the initial treatment of venous thromboembolism in patients with cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · patients with active cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Haematological Thrombocytopenia · patients with inflammatory arthritis on methotrexate
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin probably leads to higher grade III or IV thrombocytopenia compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review